By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


INSYS Therapeutics 

10220 South 51st Street
Suite 2
Phoenix  Arizona  85044  U.S.A.
Phone: 602-910-2617 Fax: 602-910-2627


Company News
Three Biotechs Face Near-Term FDA Decisions 3/21/2016 6:36:23 AM
USPTO Declines To Institute All Inter Partes Review Petitions Filed By CFAD Of INSYS U.S. Patents Directed To SUBSYS (Fentanyl Sublingual Spray) 3/10/2016 8:45:21 AM
Three Drugmakers Facing FDA Decisions This Quarter 3/9/2016 6:36:51 AM
INSYS To Present At J.P. Morgan 34th Annual Healthcare Conference 12/30/2015 11:28:53 AM
After Interviewing Current and Former Employees, Firm Releases Another Scathing Report on INSYS 12/10/2015 6:09:49 AM
INSYS Responds to Allegations It Falsified Reports to Sell More of its Cancer Pain Treatment 12/4/2015 6:02:29 AM
INSYS Therapeutics Intends to Spend $100 Million on Drug Projects in 2016 11/24/2015 5:54:35 AM
INSYS Therapeutics CEO Steps Down, New Leader Appointed 11/5/2015 6:20:47 AM
INSYS Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track Designation From FDA For The Treatment Of Opioid Intoxication Or Overdose 10/30/2015 12:45:50 PM
INSYS Therapeutics Issues Statement On Its Use Of Specialty Pharmacies 10/27/2015 12:58:11 PM